Skip to main content
Premium Trial:

Request an Annual Quote

Multiplicom CLL MASTR Plus

Multiplicom has announced the commercial release of a new gene sequencing panel, the CLL MASTR Plus kit, to improve the diagnosis of patients with chronic lymphocytic leukemia. CLL MASTR Plus detects single nucleotide variants and copy number alterations in nine genes that are frequently mutated in CLL, and is intended to provide information to guide treatment options. The identification of mutations in TP53, BIRC3, NOTCH1 and SF3B1 enables a more refined prognostic stratification, while the detection of TP53 mutations has therapeutic value as it guides treatment with alemtuzumab and/or steroids, which may be followed by allogeneic stem cell transplantation, Multiplicom noted. MASTR kits are compatible with leading NGS platforms, the company added.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.